Mangalam Drugs and Organics Ltd

₹ 27.2 -0.18%

23 Jul - close price

mangalamdrugs.com BSE: 532637 NSE: MANGALAM

About

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.^[1]

Key Points

Business Overview:^[1]
MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated
with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.

Website BSE NSE

Market Cap ₹ 43.2 Cr.
Current Price ₹ 27.2
High / Low ₹ 94.0 / 22.7
Stock P/E
Book Value ₹ 65.3
Dividend Yield 0.00 %
ROCE -14.0 %
ROE -34.8 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Stock is trading at 0.42 times its book value

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -9.39% over past five years.
Promoter holding is low: 35.6%
Company has a low return on equity of -11.0% over last 3 years.
Contingent liabilities of Rs.34.6 Cr.
Debtor days have increased from 45.3 to 63.4 days.
Promoter holding has decreased over last 3 years: -14.7%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	91	87	82	97	102	77	80	89	73	57	50	58	67
	91	91	79	90	91	68	71	80	63	62	52	60	73
Operating Profit	0	-3	2	7	12	8	9	9	10	-5	-3	-2	-5
OPM %	0%	-4%	3%	7%	11%	11%	11%	10%	14%	-8%	-6%	-3%	-8%
	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest	3	3	3	3	4	4	4	3	4	4	5	4	3
Depreciation	3	3	4	4	4	4	4	4	5	4	5	4	5
Profit before tax	-6	-10	-5	0	4	1	1	1	2	-13	-12	-10	-13
Tax %	-22%	-7%	-25%	-920%	10%	-356%	-125%	5%	91%	6%	-41%	0%	1%
	-4	-10	-4	0	4	3	3	1	0	-14	-7	-10	-13
EPS in Rs	-2.77	-6.03	-2.25	0.32	2.24	1.69	1.70	0.88	0.09	-8.67	-4.58	-6.18	-8.25
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	221	295	299	269	228	282	380	451	372	369	318	232
	200	257	252	222	218	259	327	402	347	351	282	247
Operating Profit	20	38	47	47	10	24	53	49	26	17	36	-15
OPM %	9%	13%	16%	17%	4%	8%	14%	11%	7%	5%	11%	-6%
	0	0	-0	1	0	1	5	0	0	0	0	1
Interest	10	9	10	12	9	10	9	11	13	14	15	16
Depreciation	4	4	5	7	7	8	9	10	11	15	16	18
Profit before tax	6	24	31	29	-6	6	40	28	2	-11	5	-48
Tax %	-2%	33%	29%	32%	40%	-32%	29%	29%	43%	-18%	-39%	-9%
	6	16	22	20	-8	8	28	20	1	-9	7	-44
EPS in Rs	4.66	11.15	14.08	12.57	-5.07	5.21	17.67	12.42	0.80	-5.72	4.37	-27.68
Dividend Payout %	0%	0%	0%	4%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-2%
5 Years:	-9%
3 Years:	-15%
TTM:	-27%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-739%

Stock Price CAGR
10 Years:	-17%
5 Years:	-31%
3 Years:	-37%
1 Year:	-71%

Return on Equity
10 Years:	4%
5 Years:	-4%
3 Years:	-11%
Last Year:	-35%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	14	16	16	16	16	16	16	16	16	16	16
Reserves	16	47	70	88	80	88	115	135	136	127	133	87
	78	60	66	69	65	52	70	88	89	107	96	105
	63	38	38	54	50	75	64	90	117	108	114	99
Total Liabilities	170	160	190	227	211	231	264	328	358	357	359	308
	53	54	93	102	103	101	118	135	142	147	156	152
CWIP	0	5	0	0	0	1	6	6	9	8	3	0
Investments	0	0	2	0	0	0	0	0	0	0	0	0
	117	100	95	125	107	128	140	188	206	202	201	156
Total Assets	170	160	190	227	211	231	264	328	358	357	359	308

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	14	22	43	25	22	31	28	26	38	12	43	4
	-4	-11	-39	-16	-9	-7	-31	-27	-22	-18	-19	-12
	-10	-11	-3	-9	-11	-23	3	3	-17	6	-22	6
Net Cash Flow	1	-0	0	-0	1	0	-1	1	-1	-0	2	-2
Free Cash Flow	10	11	3	9	12	24	-4	-2	16	-6	23	-8
CFO/OP	69%	68%	107%	66%	223%	129%	69%	70%	148%	71%	119%	-30%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	73	37	45	61	28	52	52	38	46	28	45	63
Inventory Days	134	85	69	132	175	121	85	139	200	185	303	239
Days Payable	128	37	38	82	77	106	63	65	139	124	199	160
Cash Conversion Cycle	79	85	75	111	126	67	74	112	107	88	148	142
Working Capital Days	26	32	19	31	21	10	23	43	38	18	13	-54
ROCE %	16%	29%	31%	25%	2%	11%	27%	18%	6%	1%	8%	-14%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Total Employees
Count

xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xxx.xx	xxx.xx	xxx.xx	xxx.xx			xxx.xx
xx	xx	xx	xx
xxx	xxx	xxx
	x.xx	xx.xx	xx.xx

Please log in to see hidden values.

Export Turnover (Foreign Exchange Earned)
INR Lakhs

Anti-Malarial API Revenue Share
% of total revenue

Top Customer Concentration
% of total revenue

Total Production Volume
Metric Tons (MT)

R&D Scientists
Count

Installed Capacity
Tonnes Per Annum (TPA)

Tenofovir Disoproxil Fumarate Production
Metric Tons (MT)

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	50.31%	50.31%	50.31%	50.31%	50.30%	50.30%	50.30%	50.30%	50.30%	35.64%	35.65%	35.65%
	0.10%	0.10%	0.26%	0.21%	0.11%	0.11%	0.47%	0.53%	0.11%	0.13%	0.32%	0.11%
	49.59%	49.59%	49.42%	49.47%	49.58%	49.58%	49.23%	49.16%	49.57%	64.22%	64.03%	64.24%
No. of Shareholders	17,978	18,610	19,173	19,312	19,508	19,679	19,697	19,728	19,881	21,227	25,140	24,465

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	50.76%	50.76%	49.27%	50.53%	50.53%	50.53%	50.31%	50.31%	50.30%	35.65%	35.65%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%	0.26%	0.47%	0.32%	0.11%
	0.19%	0.25%	1.29%	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%
	49.05%	48.99%	49.44%	49.46%	49.46%	49.36%	49.59%	49.42%	49.23%	64.03%	64.24%
No. of Shareholders	15,529	18,113	19,611	17,884	20,520	20,084	17,943	19,173	19,697	25,140	24,465

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls